[ASMB] Assembly Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 100.97 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 11.78 Change: 0.03 (0.26%)
Ext. hours: Change: 0 (0%)

chart ASMB

Refresh chart

Strongest Trends Summary For ASMB

ASMB is in the long-term down -80% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Assembly Biosciences, Inc. provides development and commercialization of gastrointestinal products in the United States. The company is developing two late-stage development product candidates, including VEN 307, a diltiazem cream for the relief of pain associated with anal fissures; and VEN 308, a phenylephrine gel for the treatment of fecal incontinence associated with ileal pouch anal anastomosis. It is also involved in the development of VEN 310 as a colonic delivery mechanism, which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules, and other treatments. The company was formerly known as Ventrus Biosciences Inc. and changed its name to Assembly Biosciences, Inc. in July, 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in New York, New York.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding17.23 M EPS-2.74 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-7.94
P/E To EPS Growth P/S P/BV0.81 Price/Cash Per Share
Price/Free Cash Flow-6.68 ROA-19.42% ROE-21.56% ROI
Current Ratio45.27 Quick Ratio Long Term Debt/Equity Debt Ratio0.02
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70.67 M Cash From Investing Activities-30 K Cash From Operating Activities-3.67 M Gross Profit
Net Profit-7.14 M Operating Profit-7.2 M Total Assets138.35 M Total Current Assets96.34 M
Total Current Liabilities2.13 M Total Debt Total Liabilities13.73 M Total Revenue
Technical Data
High 52 week31.94 Low 52 week8.36 Last close9.3 Last change3.22%
RSI24.52 Average true range0.82 Beta0.87 Volume30.34 K
Simple moving average 20 days-12.93% Simple moving average 50 days-19.04% Simple moving average 200 days-42.12%
Performance Data
Performance Week3.56% Performance Month-22.5% Performance Quart-33.67% Performance Half-42.8%
Performance Year-61.27% Performance Year-to-date-58.89% Volatility daily5.64% Volatility weekly12.6%
Volatility monthly25.83% Volatility yearly89.47% Relative Volume234.77% Average Volume271.26 K
New High New Low

News

2020-05-27 08:00:10 | Assembly Biosciences Announces Management Transition

2020-05-26 08:00:10 | Assembly Biosciences to Present During the Jefferies Virtual Healthcare Conference

2020-05-19 16:05:10 | Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020

2020-05-15 11:14:03 | Why Assembly Biosciences ASMB Stock Might be a Great Pick

2020-05-13 10:58:02 | Will Assembly Biosciences Continue to Surge Higher?

2020-05-07 16:05:10 | Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results

2020-05-06 06:33:01 | Should Assembly Biosciences NASDAQ:ASMB Be Disappointed With Their 33% Profit?

2020-05-04 08:00:10 | Preclinical Data from Assembly Biosciences’ Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal and Upcoming Journal Supplements

2020-05-01 17:00:10 | Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635c4

2020-04-30 16:05:10 | Assembly Biosciences to Host Conference Call and Webcast to Review HBV Portfolio Progress

2020-04-06 08:00:10 | Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy

2020-03-31 16:05:10 | Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635c4

2020-03-30 08:00:10 | Assembly Biosciences Appoints Jason Okazaki as Chief Legal and Business Officer

2020-03-04 18:05:11 | Assembly Biosciences ASMB Reports Q4 Loss, Tops Revenue Estimates

2020-03-04 16:05:10 | Assembly Biosciences Reports Fourth Quarter and Year End 2019 Financial Results

2020-02-20 12:31:05 | Will Assembly Biosciences ASMB Report Negative Q4 Earnings? What You Should Know

2020-02-19 08:00:10 | Assembly Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

2020-01-28 06:00:53 | Does The Assembly Biosciences, Inc. NASDAQ:ASMB Share Price Tend To Follow The Market?

2019-12-16 16:05:10 | Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

2019-12-12 07:38:44 | The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

2019-12-12 06:30:10 | Assembly Biosciences Announces Pricing of $125 Million Public Offering

2019-12-11 16:03:10 | Assembly Biosciences Announces Proposed Public Offering of Common Stock

2019-12-11 12:17:49 | Did Hedge Funds Drop The Ball On Assembly Biosciences Inc ASMB ?

2019-12-10 11:11:00 | Stock Upgrades: Assembly Biosciences Shows Rising Relative Strength

2019-12-06 08:00:10 | Assembly Biosciences Announces Plenary Lecture at HEP DART 2019

2019-11-18 08:00:00 | Assembly Biosciences Announces Presentation at Jefferies London Healthcare Conference

2019-11-11 08:00:00 | Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019

2019-11-08 16:13:07 | Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock

2019-11-07 17:30:00 | Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635c4

2019-11-07 16:05:00 | Assembly Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

2019-11-07 10:30:03 | Analysts Estimate Assembly Biosciences ASMB to Report a Decline in Earnings: What to Look Out for

2019-11-07 08:00:00 | Assembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer

2019-11-06 16:40:22 | Hedge Funds Are Selling Assembly Biosciences Inc ASMB

2019-10-31 10:47:02 | Can Segmental Growth Aid Hologic HOLX in Q4 Earnings?

2019-10-30 06:58:23 | Estimating The Fair Value Of Assembly Biosciences, Inc. NASDAQ:ASMB

2019-10-28 17:15:05 | Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635c4

2019-10-28 08:00:05 | Assembly Biosciences Appoints Thomas J. Russo as Chief Financial Officer

2019-10-18 11:02:03 | What's in Store for Thermo Fisher TMO in Q3 Earnings?

2019-10-18 10:09:02 | Top Ranked Momentum Stocks to Buy for October 18th

2019-10-17 16:27:09 | This Biotech Stock Nearly Doubled In Two Days On A Potential Hepatitis Cure

2019-10-16 07:05:00 | Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD

2019-09-23 08:14:12 | Will Assembly Biosciences Continue to Surge Higher?

2019-09-15 09:16:24 | Investors Who Bought Assembly Biosciences NASDAQ:ASMB Shares A Year Ago Are Now Down 67%

2019-08-09 16:30:00 | Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635c4

2019-08-07 08:00:00 | Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer

2019-08-05 19:25:11 | Assembly Biosciences ASMB Reports Q2 Loss, Lags Revenue Estimates

2019-08-05 16:05:00 | Assembly Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

2019-07-17 13:08:50 | Does The Assembly Biosciences, Inc. NASDAQ:ASMB Share Price Tend To Follow The Market?

2019-06-27 07:05:00 | Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis

2019-06-25 16:05:00 | Assembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit